Department of Interventional Cardiology, AP-HP, Henri Mondor University Hospital, Créteil, France.
JACC Cardiovasc Interv. 2013 May;6(5):479-86. doi: 10.1016/j.jcin.2013.02.007.
This study sought to assess whether the volume of contrast media (CM) influences the occurrence of acute kidney injury (AKI) following transcatheter aortic valve implantation (TAVI).
The volume of CM has been shown to be associated with increasing risk of AKI; however, in a high-risk elderly TAVI population, the predictive value and optimal threshold of CM dose on AKI remain uncertain.
Data of 415 consecutive transfemoral TAVI patients (age 83.6 ± 6.8 years, logistic EuroSCORE 23.0 ± 12.2%) were analyzed. AKI was defined by Valve Academic Research Consortium criteria. Based on a previous formula, the ratio of CM to serum creatinine (SCr) and body weight (BW) (CM × SCr/BW) was calculated as defining the degree of CM use. The association between CM dose and incidence of AKI, as well as predictive factors and prognosis of AKI, were investigated.
AKI occurred in 63 patients (15.2%). Cumulative 1-year mortality showed significant differences between the AKI and non-AKI groups (47.9% vs. 15.7%, p < 0.001). Mean CM × SCr/BW ratio was higher in the AKI group than in the non-AKI group (4.1 ± 2.9 vs. 2.9 ± 1.6, p < 0.001). By multivariate analysis, CM × SCr/BW per 1.0 increase, ejection fraction <40%, and transfusion were associated with the occurrence of AKI (odds ratio [OR]: 1.16; 95% confidence interval [CI]: 1.03 to 1.20; p = 0.017, OR: 3.01; 95% CI: 1.49 to 5.00; p = 0.001, OR: 2.73; 95% CI: 1.54 to 6.15; p = 0.001, respectively). A threshold value of CM × SCr/BW for predicting AKI was statistically identified as 2.7.
Although mechanisms of AKI following TAVI are multifactorial, the present study identified a relationship between CM dose increment and high prevalence of AKI. Therapeutic efforts not to exceed the threshold value may reduce the risk of AKI.
本研究旨在评估经导管主动脉瓣植入术(TAVI)后对比剂(CM)用量是否会影响急性肾损伤(AKI)的发生。
已有研究表明 CM 用量与 AKI 风险增加相关;然而,在高危老年 TAVI 人群中,CM 剂量对 AKI 的预测价值和最佳阈值尚不确定。
分析了 415 例连续行经股 TAVI 的患者(年龄 83.6±6.8 岁,逻辑 EuroSCORE 23.0±12.2%)的数据。AKI 采用 Valve Academic Research Consortium 标准定义。根据之前的公式,计算 CM 与血清肌酐(SCr)和体重(BW)的比值(CM×SCr/BW)作为 CM 使用程度的定义。研究了 CM 剂量与 AKI 发生率之间的关系,以及 AKI 的预测因素和预后。
63 例患者(15.2%)发生 AKI。AKI 组和非 AKI 组的 1 年累积死亡率有显著差异(47.9% vs. 15.7%,p<0.001)。AKI 组的 CM×SCr/BW 比值高于非 AKI 组(4.1±2.9 vs. 2.9±1.6,p<0.001)。多因素分析显示,CM×SCr/BW 每增加 1.0、射血分数<40%和输血与 AKI 的发生相关(比值比[OR]:1.16;95%置信区间[CI]:1.03 至 1.20;p=0.017,OR:3.01;95%CI:1.49 至 5.00;p=0.001,OR:2.73;95%CI:1.54 至 6.15;p=0.001)。CM×SCr/BW 预测 AKI 的截断值为 2.7。
尽管 TAVI 后 AKI 的发生机制是多因素的,但本研究发现 CM 剂量增加与 AKI 高发之间存在关联。不超过阈值的治疗努力可能会降低 AKI 的风险。